VICTORIA, BC / ACCESSWIRE / November 26, 2024 / AI/ML Innovations Inc. ("AI/ML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that that it has completed its previously ...

SIDHE Institute Launches Groundbreaking Research and Transformative Programs Merging Ancient Wisdom with Modern Science to ...

The microbiome communicates with the gut, the brain and the immune system using microbial metabolites such as short-chain ...

Disposal/Strategic Company DecisionMarinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals26-Nov-2024 / 21:14 CET/CESTDisclosure of an inside ...

Renowned Facial Plastic Surgeon Dr. Rubinstein has been selected to train professionals on FDA-approved BOTOX® Cosmetic for neck rejuvenation in New Jersey.  MONTVALE, NJ / ACCESSWIRE / November 26, ...

The CDC estimates approximately 385,000 needlestick and sharps-related injuries among U.S. healthcare workers each year BEAUMONT, TX / ACCESSWIRE / November 26, 2024 / Due to an alarming rise in ...

Aston University and Women and Children’s Hospital developing new devices to improve drug treatment 26 November 2024 | Birmingham, UKThe new device is designed to reduce the risk of injuries when ...

Policy Recommendations to Reduce the Burden of COPD, calling for solutions to tackle the urgent challenge of chronic obstructive pulmonary disease (COPD), affecting 2% of the UK population, with many ...

ROCKVILLE, MD / ACCESSWIRE / November 26, 2024 / Dr. Roy Rubinfeld, an internationally renowned corneal surgeon and innovator, has developed a groundbreaking epithelium-on corneal cross-linking ...

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ ...

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite ...

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come ...